Patents Examined by Janet L Coppins
  • Patent number: 10441571
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 10441572
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 10441553
    Abstract: The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 15, 2019
    Assignees: UNIVERSIDADE DE SAO PAULO—USP, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL—UFRGS, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JESUSALEM LTD
    Inventors: Raphael Mechoulam, Antonio Waldo Zuardi, Flavio Pereira Kapczinski, Jaime Eduardo Cecilio Hallak, Francisco Silveira Guimaraes, Jose Alexandre de Souza Crippa, Aviva Breuer
  • Patent number: 10406137
    Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 10, 2019
    Assignee: Siga Technologies Inc.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A.C.L.S. Anderson, William C. Weimers, Dylan Nelson, Tove′ C. Bolken, Dennis E. Hruby, Michael H. O'Neill, Gary Sweetapple, Kelley A. McCloughan
  • Patent number: 10398674
    Abstract: An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 3, 2019
    Inventors: Henry Lowe, Ngeh J. Toyang
  • Patent number: 10383871
    Abstract: Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 20, 2019
    Assignee: Vernalis (R&D) Ltd.
    Inventors: Stephen Roughley, Steven Walls, Terance Hart, Rachel Parsons, Paul Brough, Christopher Graham, Alba Macias
  • Patent number: 10369127
    Abstract: A method for inhibiting the expression and/or functional activity of an ABC transporter protein in a subject suffering from a disorder associated with an overexpression of the ABC transporter protein includes administrating a cobalt-polypyridyl complex to the subject. A method for inhibiting the expression and/or functional activity of an ABC transporter in cells includes contacting the cells with an effective amount of the cobalt-polypyridyl complex.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: August 6, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Kam Wai Wong, Yuen Kwan Law, Man Chung Wong
  • Patent number: 10368546
    Abstract: The present invention relates to novel fungicidal compositions for the treatment of phytopathogenic diseases of useful plants, especially phytopathogenic fungi, and to a method of controlling such phytopathogenic diseases on useful plants. In particular compositions suitable for control of diseases caused by phytopathogens comprise a mixture of a compound of formula (I) with a compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants using such compositions.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 6, 2019
    Assignee: Syngenta Participations AG
    Inventors: Gina Mercia Swart, Michael Oostendorp
  • Patent number: 10350207
    Abstract: The invention provides compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells. The drug combinations described herein can be synergistic and can have lower neurotoxicity effects than the same amounts of other compounds and combinations of compounds, and can be effective when a particular cancer has become resistant to previously administered therapies.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: July 16, 2019
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Jessie Peh
  • Patent number: 10328076
    Abstract: The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 25, 2019
    Assignee: PHARMATHEN S.A.
    Inventor: Evangelos Karavas
  • Patent number: 10300056
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: May 28, 2019
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
  • Patent number: 10300066
    Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 28, 2019
    Assignee: Zhejiang DTRM Biopharma Co. Ltd.
    Inventor: Wei He
  • Patent number: 10292987
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 21, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Patent number: 10292387
    Abstract: A tick removal ointment which is a topical composition having 25% benzocaine incorporated in white petroleum jelly. The amount of benzocaine in the tick removal ointment is efficacious for numbing the tick and hence causes the tick to release or self-extricate from the host mammal, optimally prior to the transmission of disease organisms from the tick to the host mammal. Upon the self-extrication of the tick from the host mammal, the white petroleum jelly is efficacious for killing the tick. Application of the present tick removal ointment eliminates the need to make direct contact with the tick to remove the tick and further eliminates the task of observing the mammal for a ii period of time because the composition is devised to first release the tick from the host mammal and then to kill the tick once the tick is released from the host mammal.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: May 21, 2019
    Inventor: James Dill
  • Patent number: 10292952
    Abstract: Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: May 21, 2019
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10251880
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 9, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Patent number: 10251876
    Abstract: The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 9, 2019
    Inventors: Shanchun Wang, Xunqiang Wang, Hongmei Gu, Ping Dong, Hongjiang Xu
  • Patent number: 10213430
    Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Patent number: 10206401
    Abstract: The present invention relates to novel pyridine compounds of the formulae I and II, to their salts, to their tautomers, to their N-oxides, and to the salts of these N-oxides or tautomers. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests. The invention also relates to a method for controlling invertebrate pests by using these compounds. The invention further relates to plant propagation material and to agricultural compositions comprising said compounds wherein A is a radical of the formulae A1, A2, A3, A4, A5 or A6 wherein # denotes the binding site to the remainder of formulae I or II; Z is O, S or N—RN; X1 is S, O or NRa; X2 is OR2a, NR2bR2c, S(O)mR2d; X3 is a lone pair or oxygen; R1, R2 and R3 are, inter alia, hydrogen, and RA1, RA2 RA3 RA4, RA5, RA6 and RN, are as defined in claim 1.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 19, 2019
    Assignee: BASF SE
    Inventors: Sebastian Soergel, Christian Defieber, Ronan Le Vezouet, Steffen Gross, Karsten Koerber, Deborah L. Culbertson, Douglas D. Anspaugh
  • Patent number: 10206872
    Abstract: A method of treating a patient in need of therapy with fentanyl or a salt thereof, the method comprising providing a ready-to-administer solution consisting essentially of fentanyl or a salt thereof as the sole active ingredient, a sugar or sugar alcohol and water for injection, the solution having a pH in the range of 3.5 to 7.5, and parenterally administering the solution to the patient.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: February 19, 2019
    Assignee: SUN PHARMACUETICAL INDUSTRIES LTD.
    Inventors: Samarth Kumar, Prashant Kane, Subhas Balaram Bhowmick, Milan Natvarbhai Thakkar, Kandarp Maheshkumar Dave